32 patents
Utility
ANTI-IL-13RALPHA2 Conjugates
14 Sep 23
This disclosure relates to antibody conjugates comprising antibodies that bind specifically to the Interleukin-13 receptor subunit alpha-2 (IL-13Rα2) protein, conjugated to cytotoxic warheads, and associated uses.
Patricius Hendrikus Cornelis VAN BERKEL, Ian KIRBY
Filed: 16 Nov 22
Utility
Anti-psma Conjugates
29 Jun 23
This disclosure relates to antibody conjugates comprising antibodies that bind specifically to prostate-specific membrane antigen (PSMA), conjugated to cytotoxic warheads, and associated uses.
Patricius Hendrikus Cornelis VAN BERKEL, Ian KIRBY
Filed: 16 Nov 22
Utility
Combination Therapy
18 May 23
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Jay Marshall FEINGOLD, Patricius Hendrikus Cornelis VAN BERKEL, Jens WUERTHNER, John HARTLEY, Francesca ZAMMARCHI
Filed: 11 Aug 22
Utility
Combination Therapy
27 Apr 23
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis VAN BERKEL, Francesca ZAMMARCHI, John HARTLEY
Filed: 8 Jul 19
Utility
Dosage Regime
6 Apr 23
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs).
Jay Marshall FEINGOLD, David Rodney UNGAR
Filed: 5 Oct 22
Utility
Combination Therapy
30 Mar 23
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis VAN BERKEL, Francesca ZAMMARCHI, Jens WUERTHNER
Filed: 6 Nov 20
Utility
Pyrrolobenzodiazepine-antibody Conjugates
23 Feb 23
The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.
Patricius Hendrikus Cornelis VAN BERKEL
Filed: 3 Jun 22
Utility
Dosage Regimes
9 Feb 23
The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs).
Jay Marshall FEINGOLD, Jens WUERTHNER
Filed: 15 Jul 22
Utility
Pyrrolobenzodiazepine Resistance
3 Nov 22
The present disclosure relates to methods of determining if a proliferative disorder such as cancer is resistant to treatment with a pyrrolobenzodiazepine (PBD) agent, such as a therapeutic antibody-drug conjugate (ADC) comprising a PBD warhead conjugated to an antibody (PBD-ADC).
John Hartley
Filed: 18 Dec 19
Utility
Combination Therapy Comprising an ANTI-CD19 Antibody Drug Conjugate and a PI3K Inhibitor or a Secondary Agent
29 Sep 22
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Francesca ZAMMARCHI, Francesco BERTONI
Filed: 8 Jun 20
Utility
Dosage Regimes for the Administration of an ANTI-CD19 Adc
8 Sep 22
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs).
Jay Marshall Feingold, David Rodney Ungar
Filed: 18 Mar 22
Utility
Treatment of Car T-cell Toxicity
9 Jun 22
The present disclosure relates to methods for improving the safety profile of adoptive cell transfer therapies.
Tomasz Sablinski
Filed: 8 Feb 19
Utility
Molecular Adjuvant
14 Apr 22
The present disclosure relates to therapies for the treatment of a disorders characterized by a disorder-associated antigen (DAA); vaccination methods are disclosed.
Patrick Hendrikus Cornelis VAN BERKEL, Jay Marshall FEINGOLD, Jens WUERTHNER, James ADAMS
Filed: 22 May 19
Utility
Pyrrolobenzodiazepine-antibody Conjugates and Uses Thereof
31 Mar 22
The present disclosure relates to novel pyrrolobenzodiazepine antibody-drug conjugates (PBD-ADCs) and therapeutic uses thereof.
Patricius Hendrikus Cornelis van Berkel, Persis Amrolia, Kerry Chester, Jenny Yeung
Filed: 22 Sep 21
Utility
ANTI-IL13R ALPHA2 Antibodies
3 Feb 22
This disclosure relates to antibodies that specifically bind to the Interleukin-13 receptor subunit alpha-2 (IL13Rα2) protein, and associated uses and methods for production.
Patricius Hendrikus Cornelis Van Berkel, Francois Bertelli
Filed: 30 Jul 21
Utility
Combination Therapy with an ANTI-CD25 Antibody-drug Conjugate
20 Jan 22
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley
Filed: 20 Apr 18
Utility
Pyrrolobenzodiazepine-antibody Conjugates
20 Jan 22
The present disclosure relates to pyrrolobenzodiazepines (PBDs) having a labile C2 or N10 protecting group in the form of a linker to an antibody.
Patricius Hendrikus Cornelis VAN BERKEL
Filed: 20 Jul 21
Utility
Pyrrolobenzodiazepine-antibody Conjugates
13 Jan 22
Patricius Hendrikus Cornelis VAN BERKEL
Filed: 24 Sep 21
Utility
Combination Therapy
21 Oct 21
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Francesca ZAMMARCHI, Francesco BERTONI
Filed: 30 Aug 19
Utility
Pyrrolobenzodiazepine-antibody Conjugates
22 Apr 21
The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD, John HARTLEY
Filed: 28 Aug 20